Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Post-Macugen, Still In-Licensing to Uncover Value in Ophthalmology

This article was originally published in Start Up

Executive Summary

The lesson that entrepreneurs and VCs seem to be taking from the fast-paced ophthalmology sector is the need for shorter development time frames and clinical candidates with reduced risk. Among others, MacuSight, Danube, and Lux, profiled here, are to one extent or another revisiting the existing pharmacopeia to test ophthalmic indications for existing compounds.

You may also be interested in...



Imagen's Ophthalmology In-Licensing Strategy Attracts $40M Series A

With a plan to take advantage of scientific advances suggesting that compounds for cancer and other diseases may have facility in the eye, Imagen will seek ideal candidates for dry AMD.

Imagen's Ophthalmology In-Licensing Strategy Attracts $40M Series A

With a plan to take advantage of scientific advances suggesting that compounds for cancer and other diseases may have facility in the eye, Imagen will seek ideal candidates for dry AMD.

Imagen Biotech Inc.

With time to exit an increasingly important metric for VCs, jump-starting new companies via in-licensing remains an important and oft-used strategy. Such derisking is one of the defining principles behind Imagen Biotech, a new ophthalmic play still operating in stealth mode. Imagen plans to pursue new leads for sight-threatening diseases, including dry age-related macular degeneration.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091290

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel